Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (29205)	8/19/1999 11:03:00 PM
From: Henry Niman	Respond to of 32384

Thanks for the link to the NPR breast cancer program sciencefriday.com As most readers of this board know, LGND is heavily into SERMs. LGND gets milestone and royalty payments on 4 that are in the clinic (PFE's Droloxifene and CP-366,156 as well as AHP's TSE424 and ERA923). In addition to the 4 SERMs in clinical trials, LGND has a research agreement with LLY to develop combination treatments involving second generation Rexinoids and 2nd generation SERMs. LLY's 1st generation SERM, Evista (Raloxifene) is in a head to head breast cancer prevention program being underwritten by the government (NSABP sponsored trial). LGND of course has a large Targretin trial for advanced breast cancer cancernet.nci.nih.gov involving some of the best Breast Cancer centers in the world cancernet.nci.nih.gov which is being chaired by George Daniel Demetri, Principal Investigator, Ph: 617-632-3985 Dana-Farber Cancer Institute Boston, Massachusetts, USA

To: D.Lu who wrote (29205)	8/19/1999 11:57:00 PM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

Most readers of this board will also recognize guest speaker, Donald McDonnell, former LGND employee and inventor of key patent on the progesterone receptor 164.195.100.11 The patent is assigned to LGND and forms the bases for some of the more recent studies which will probably be discussed on the show. McDonnell was also an inventor on an earlier patent done in collaboration with Bert O'Malley, another LGND consultant and another leader in the field of steroid hormone receptors. Not sure how many NPR listeners will catch the connections, but readers of this board should know that most of the information being discussed tomorrow focuses on transcription control via intracellular recepters, a field led by Ligand's scientist and consultants.